Brief: Point Biopharma Provides Updated Efficacy And Safety Data From The Lead-In Cohort Of The Phase 3 Splash Trial In MCRPC

POINT Biopharma Global

10/09/2022 10:14

Sept 10 (Reuters) - POINT Biopharma Global Inc  PNT.O :
    * POINT BIOPHARMA PROVIDES UPDATED EFFICACY AND SAFETY DATA
FROM
THE LEAD-IN COHORT OF THE PHASE 3 SPLASH TRIAL IN MCRPC AT ESMO
CONGRESS 2022
    * POINT BIOPHARMA - KEY FINDINGS INCLUDE A MEDIAN RPFS TIME
OF
11.5 MONTHS, ALONG WITH A WELL-TOLERATED SAFETY PROFILE WITH NO
TREATMENT-RELATED DEATHS

Source text for Eikon:  ID:nGNXbYzhlK 
Further company coverage:  PNT.O 

 ((Reuters.Briefs@thomsonreuters.com;))